GlassScriptPhysician profile
James C Vonthron
NPI 1881680825
$726.77
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $22.42 · 2021: $101 · 2022: $269.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252.70 | 2019-2022 | |
| Aspira Women'S Health INC | $71.17 | 2022 | |
| Mylan Pharmaceuticals INC. | $67.44 | 2019-2022 | |
| Pfizer INC. | $40.55 | 2019-2021 | |
| Therapeuticsmd, INC. | $36.55 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.35 | 2019-2022 | |
| Organon LLC | $27.29 | 2022 | |
| Covidien LP | $26.93 | 2019 | |
| Alydia Health | $24.06 | 2021 | |
| Myovant Sciences INC. | $23.80 | 2022 | |
| Evofem Biosciences, INC. | $17.76 | 2022 | |
| Hologic Sales and Service, LLC | $14.44 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.07 | 2019 | |
| Avion Pharmaceuticals | $13.32 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.95 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $12.65 | 2019 | |
| Ascend Therapeutics US, LLC | $12.00 | 2021 | |
| Glaxosmithkline, LLC. | $11.62 | 2019 | |
| Millicent US INC | $11.12 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vonthron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.